Company Introduction-Dalian Yongda Suli Pharma Co., Ltd

language

ABOUT US

Home

Company Introduction

Dalian Yongda Suli Pharma Co., Ltd. Established in December 2020, it was jointly invested and established by Suli Pharmaceutical Technology Jiangyin Co., Ltd., a wholly-owned subsidiary of Suli Group, and Jiangsu Yongda Pharmaceutical Co., Ltd.

Jiangsu Yongda Pharmaceutical was founded in 2001 and is a pharmaceutical enterprise specializing in the production, sales, and service of chemical raw materials and intermediates. The company is equipped with high-quality equipment and sophisticated testing instruments, and implements a quality management system that meets domestic and foreign GMP requirements. Relying on the two major technical characteristics of high-pressure hydrogenation reaction and enzyme catalytic reaction, as well as the advantages of large-scale production, it has become an important production base and one of the main suppliers of quinolone antibacterial raw materials, narglinide raw materials, perindopril raw materials, and intermediates at home and abroad. It enjoys a good reputation and reputation among domestic and foreign customers, and its products are sold to multiple countries and regions around the world. The company has already obtained national GMP certification for five active pharmaceutical ingredients.

Suli Pharmaceutical Technology Jiangyin Co., Ltd. is a wholly-owned subsidiary of Suli Group. It is a CRO/CDMO service company that provides drug research and development, pilot testing, and production services, providing customers with product synthesis, development, and production services ranging from laboratory grade to ton grade. Relying on its rich experience and technical expertise in process research and development, Suli Pharmaceutical has gradually established a good reputation in the industry and established cooperative relationships with many innovative pharmaceutical companies both domestically and internationally. At the same time, the company has gradually established an asymmetric catalytic synthesis chiral technology platform and a special fluorination reagent development platform, accelerating the industrialization of cutting-edge and innovative technologies, and utilizing innovative technologies to provide chiral and fluorination structure synthesis for more new drug molecules.

Dalian Yongda Suli Pharma Co., Ltd. will work together to build a production base for active pharmaceutical ingredients and intermediates on a larger scale with better quality and safety management. We will continue to provide customers with catalog products and CDMO services with stable quality, higher cost-effectiveness, and better service. The company officially started trial production in the first quarter of 2024 and plans to pass the GMP audit of the national bureau in 2025. At the same time, the company will submit DMF applications for multiple active pharmaceutical ingredients and pass the audit of the US FDA as soon as possible. In addition, the company will strictly implement the EHS management system, strictly handle the three wastes in accordance with national standards and park requirements, attach great importance to employee health and safety, and fulfill corporate social responsibilities while ensuring quality and quantity.

The company will continue to expand the construction of new technology platforms such as high-pressure hydrogenation, enzyme catalysis, chiral synthesis, and new fluorination, with technical support from the Shanghai R&D center. Based on the process research and development experience of the R&D team, the company will continue to provide CRO/CDMO services such as route design, process development, process safety assessment, and production amplification for domestic and foreign customers.

Yongda Suli Pharma will continuously pursue innovation, achieve green, efficient, and economical innovative synthesis processes, adhere to the principles of "lean management and strict control", and become a "reassuring drug" for society, benefiting the people and contributing to human health.